Note: An erratum for this article is available here.
The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis
Version of Record online: 12 MAY 2003
British Journal of Clinical Pharmacology
Volume 55, Issue 6, pages 639–642, June 2003
How to Cite
Lee, D. K. C., Haggart, K., Currie, G. P., Anderson, S. D. and Lipworth, B. J. (2003), The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. British Journal of Clinical Pharmacology, 55: 639–642. doi: 10.1046/j.1365-2125.2003.01807.x
- Issue online: 12 MAY 2003
- Version of Record online: 12 MAY 2003
- Received 9 July 2002, accepted 26 November 2002.
- allergic rhinitis;
- nasal hyper-reactivity
Aims It is unclear as to which mediators are involved in mediating the response to nasal mannitol challenge, a novel osmotic stimulus.
Methods A double-blind, randomized, placebo-controlled, crossover design was employed. Nine patients with allergic rhinitis were randomized to receive a single-dose of desloratadine 5 mg, montelukast 10 mg or placebo, and underwent nasal mannitol challenges with nasal peak inspiratory flow recordings over 60 min. The change in peak nasal inspiratory flow was calculated as percentage change from baseline as the peak response and area under the time–response curve (AUC).
Results Desloratadine and montelukast conferred a significant degree of protection compared to placebo for peak and AUC response, but there were no significant differences between the two drugs. For the peak response as percentage fall, the mean difference (95% CI) vs placebo was 27.7 (8.0, 47.4)% for desloratadine and 17.6 (1.9, 33.3)% for montelukast.
Conclusions Our results suggest that histamine and cysteinyl-leukotrienes are involved in mediating the response to nasal mannitol in allergic rhinitis.